User profiles for Anna Stainer
Anna StainerHumanitas University Verified email at hunimed.eu Cited by 586 |
[HTML][HTML] Molecular biomarkers in idiopathic pulmonary fibrosis: state of the art and future directions
A Stainer, P Faverio, S Busnelli, M Catalano… - International Journal of …, 2021 - mdpi.com
Idiopathic pulmonary fibrosis (IPF), the most lethal form of interstitial pneumonia of unknown
cause, is associated with a specific radiological and histopathological pattern (the so-called “…
cause, is associated with a specific radiological and histopathological pattern (the so-called “…
Six-month pulmonary impairment after severe COVID-19: a prospective, multicentre follow-up study
Background: Long-term pulmonary sequelae following severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) pneumonia are not yet confirmed; however, preliminary …
coronavirus 2 (SARS-CoV-2) pneumonia are not yet confirmed; however, preliminary …
[HTML][HTML] Characterizing non-tuberculous mycobacteria infection in bronchiectasis
P Faverio, A Stainer, G Bonaiti, SC Zucchetti… - International journal of …, 2016 - mdpi.com
Chronic airway infection is a key aspect of the pathogenesis of bronchiectasis. A growing
interest has been raised on non-tuberculous mycobacteria (NTM) infection. We aimed at …
interest has been raised on non-tuberculous mycobacteria (NTM) infection. We aimed at …
[HTML][HTML] One-year pulmonary impairment after severe COVID-19: a prospective, multicenter follow-up study
Background Long-term pulmonary sequelae following hospitalization for SARS-CoV-2
pneumonia is largely unclear. The aim of this study was to identify and characterise pulmonary …
pneumonia is largely unclear. The aim of this study was to identify and characterise pulmonary …
[HTML][HTML] Efficacy of pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis: a systematic review
Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary
fibrosis treatment by regulatory agencies and available for clinical use worldwide. These …
fibrosis treatment by regulatory agencies and available for clinical use worldwide. These …
[HTML][HTML] Lung microbiome in idiopathic pulmonary fibrosis and other interstitial lung diseases
Interstitial lung diseases represent a heterogeneous and wide group of diseases in which
factors leading to disease initiation and progression are not fully understood. Recent evidence …
factors leading to disease initiation and progression are not fully understood. Recent evidence …
[HTML][HTML] Management of chronic respiratory failure in interstitial lung diseases: overview and clinical insights
…, F De Giacomi, G Bonaiti, A Stainer… - … Journal of Medical …, 2019 - ncbi.nlm.nih.gov
… Paola Faverio, 1 Federica De Giacomi, 1 Giulia Bonaiti, 1 Anna Stainer, 1 Luca Sardella,
1 Giulia Pellegrino, 2 Giuseppe Francesco Sferrazza Papa, 2 Francesco Bini, 3 Bruno Dino …
1 Giulia Pellegrino, 2 Giuseppe Francesco Sferrazza Papa, 2 Francesco Bini, 3 Bruno Dino …
Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma
…, L Scolamiero, S Morris, A Bowman, A Stainer… - …, 2020 - academic.oup.com
Objectives Cytokines released by infiltrating T cells may promote mechanisms leading to
fibrosis in scleroderma. The aim of this study was to investigate the role of the Th2 cytokine IL-…
fibrosis in scleroderma. The aim of this study was to investigate the role of the Th2 cytokine IL-…
Treatable traits in interstitial lung diseases: a call to action
Comment 126 www. thelancet. com/respiratory Vol 11 February 2023 therefore be amenable
to similar treatment strategies. 1, 2 This evidence points to the existence of treatable traits—…
to similar treatment strategies. 1, 2 This evidence points to the existence of treatable traits—…
Nontuberculous mycobacterial pulmonary disease: an integrated approach beyond antibiotics
…, F De Giacomi, BD Bodini, A Stainer… - ERJ Open …, 2021 - Eur Respiratory Soc
Nontuberculous mycobacterial (NTM) pulmonary disease (PD) is an emerging condition with
heterogeneous manifestations from both the microbiological and the clinical point of view. …
heterogeneous manifestations from both the microbiological and the clinical point of view. …